Evan McMenamin said his brother Travis, "never lets it get him down" despite the "incredible challenges" he faces ...

Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands ...

Some of the market’s biggest winners start off as the smallest players. While trillion-dollar tech giants like the ...

There is an unmet need for therapies targeting Duchenne muscular dystrophy (DMD)–related heart disease, and phase 2 results ...

The disabled community in Hollywood reminds their able-bodied colleagues to help join in the fight for equality and inclusion ...

Blizzard Entertainment and World of Warcraft players raised over $2 million for CureDuchenne, honoring Mats Steen, a devoted player lost to Duchenne muscular dystrophy, while promoting awareness and ...

Patient advocate Austin Leclaire, who died Feb. 1, played a pivotal role in spurring the development of the first medicines ...

Blizzard's Revenant Pack raises over $2 million for CureDuchenne! Discover how gaming communities made a real-world impact.

Percheron Therapeutics says it will abandon its lead drug candidate altogether, following December's Duchenne muscular dystrophy trial flop.

Despite the obstacles, Riley Herrera had a life filled with family, sports, travel, faith and hope before his death on Nov.

Cumberland Pharmaceuticals' Phase 2 trial shows ifetroban improves heart function in Duchenne muscular dystrophy patients.